GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Thyrocare Technologies Ltd (NSE:THYROCARE) » Definitions » Operating Income

Thyrocare Technologies (NSE:THYROCARE) Operating Income : ₹1,351 Mil (TTM As of Mar. 2025)


View and export this data going back to 2016. Start your Free Trial

What is Thyrocare Technologies Operating Income?

Thyrocare Technologies's Operating Income for the three months ended in Mar. 2025 was ₹439 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2025 was ₹1,351 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Thyrocare Technologies's Operating Income for the three months ended in Mar. 2025 was ₹439 Mil. Thyrocare Technologies's Revenue for the three months ended in Mar. 2025 was ₹1,872 Mil. Therefore, Thyrocare Technologies's Operating Margin % for the quarter that ended in Mar. 2025 was 23.47%.

Warning Sign:

Thyrocare Technologies Ltd operating margin has been in a 5-year decline. The average rate of decline per year is -13.5%.

Thyrocare Technologies's 5-Year average Growth Rate for Operating Margin % was -13.50% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Thyrocare Technologies's annualized ROC % for the quarter that ended in Mar. 2025 was 19.06%. Thyrocare Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was 83.65%.


Thyrocare Technologies Operating Income Historical Data

The historical data trend for Thyrocare Technologies's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Thyrocare Technologies Operating Income Chart

Thyrocare Technologies Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,411.30 2,018.60 846.20 904.20 1,351.00

Thyrocare Technologies Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 207.50 312.80 352.20 246.70 439.20

Thyrocare Technologies Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1,351 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Thyrocare Technologies  (NSE:THYROCARE) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Thyrocare Technologies's annualized ROC % for the quarter that ended in Mar. 2025 is calculated as:

ROC % (Q: Mar. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2024 ) + Invested Capital (Q: Mar. 2025 ))/ count )
=1756.8 * ( 1 - 54.3% )/( (0 + 4211.7)/ 1 )
=802.8576/4211.7
=19.06 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Thyrocare Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2024  Q: Mar. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=1915.2/( ( (0 + max(0, 0)) + (1983.1 + max(306.5, 0)) )/ 1 )
=1915.2/( ( 0 + 2289.6 )/ 1 )
=1915.2/2289.6
=83.65 %

where Working Capital is:

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0 + 0 + 0)
=0

Working Capital(Q: Mar. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(465.4 + 730 + 251.9) - (785.9 + 0 + 354.9)
=306.5

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2025) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Thyrocare Technologies's Operating Margin % for the quarter that ended in Mar. 2025 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2025 )/Revenue (Q: Mar. 2025 )
=439.2/1871.6
=23.47 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Thyrocare Technologies Operating Income Related Terms

Thank you for viewing the detailed overview of Thyrocare Technologies's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Thyrocare Technologies Business Description

Traded in Other Exchanges
Address
D-37/3, TTC Industrial Area, MIDC, Turbhe, Opposite Sandoz, Navi Mumbai, MH, IND, 400703
Thyrocare Technologies Ltd is a diagnostics & research company. The company has three business segments: Diagnostic Testing Services, Imaging Services, and Others. The Diagnostic Testing Services segment provides a medical diagnostic investigation into thyroid disorders, metabolism disorders, diabetes, anemia, infertility, auto-immunity, and other infectious diseases. The company majorly earns the majority of its revenue from the Diagnostic Testing Services segment. The Imaging Services segment operates a network of imaging centers focused on early and effective cancer monitoring. The Other business segment provides miscellaneous services. The company earns the vast majority of its revenue in India.

Thyrocare Technologies Headlines

No Headlines